Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.86 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.86 |
| ▸ | BCL6 | P41182 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183176 | 0.92 | KCNN3 (1.00) | KCNN3KCNN2BCL6GRM5SMN1; SMN2 | |
| SCHEMBL30421528 | 0.92 | KCNN3 (1.00) | KCNN3KCNN2BCL6GRM5SMN1; SMN2 | |
| SCHEMBL183288 | 0.87 | KCNN3 (0.78) | KCNN3KCNN2BCL6GRM5GAA | |
| SCHEMBL183680 | 0.83 | KCNN3 (0.72) | KCNN3KCNN2BCL6GRM5YTHDC1 | |
| SCHEMBL183250 | 0.83 | KCNN3 (0.72) | KCNN3KCNN2BCL6GRM5LMNA | |
| SCHEMBL183151 | 0.82 | KCNN3 (0.82) | KCNN3KCNN2BCL6SMN1; SMN2LMNA | |
| SCHEMBL2881387 | 0.81 | KCNN3 (0.80) | KCNN3KCNN2BCL6GRM5YTHDC1 | |
| SCHEMBL183069 | 0.81 | KCNN3 (0.80) | KCNN3KCNN2BCL6SMN1; SMN2LMNA | |
| SCHEMBL183385 | 0.81 | KCNN3 (0.80) | KCNN3KCNN2BCL6SMN1; SMN2LMNA | |
| SCHEMBL182996 | 0.81 | KCNN3 (0.80) | KCNN3KCNN2BCL6SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | claimed |
| CN-101646669-B | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS | 2013-09-04 | — | — | CN | claimed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | claimed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | claimed |
| CN-101646669-A | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS DK | 2010-02-10 | — | — | CN | claimed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-8362024-B2 | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| CN-101646669-A | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS DK | 2010-02-10 | — | — | CN | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KCNN3 15/4885KCNN2 5/4885BCL6 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.